Skip to main content

Articles

Page 1 of 12

  1. Fibromyalgia is a chronic rheumatic disease of unknown aetiology, highly disabling and mainly affecting women. The aim of our work is to estimate, on a national scale, the economic impact of this disease on th...

    Authors: J Oliva-Moreno and C Vilaplana-Prieto
    Citation: Health Economics Review 2024 14:51
  2. Since 2017, immune checkpoint inhibitors (ICIs) have been available for the treatment of advanced hepatocellular carcinoma (HCC) or unresectable HCC, but their adoption into national medical insurance programs...

    Authors: Hongyu Gong, Siew Chin Ong, Fan Li, Yan Shen, Zhiying Weng, Keying Zhao, Zhengyou Jiang and Meng Wang
    Citation: Health Economics Review 2024 14:48
  3. Significant gaps in scholarship on the cost-benefit analysis of haemodialysis exist in low-middle-income countries, including Nigeria. The study, therefore, assessed the cost-benefit of haemodialysis compared ...

    Authors: Yakubu Adole Agada-Amade, Daniel Chukwuemeka Ogbuabor, Eric Obikeze, Ejemai Eboreime and Obinna Emmanuel Onwujekwe
    Citation: Health Economics Review 2024 14:47
  4. Given the rapid population aging in China, achieving universal health coverage (UHC) presents a primary challenge in addressing unmet healthcare needs and associated inequalities among middle-aged and older ad...

    Authors: Yunhan Wang, Nan Jiang, Haiya Shao and Zhonghua Wang
    Citation: Health Economics Review 2024 14:46
  5. Hospital services are typically reimbursed using case-mix tools that group patients according to diagnoses and procedures. We recently developed a case-mix tool (i.e., the Queralt system) aimed at supporting c...

    Authors: Júlia Folguera, Elisabet Buj, David Monterde, Gerard Carot-Sans, Isaac Cano, Jordi Piera-Jiménez and Miquel Arrufat
    Citation: Health Economics Review 2024 14:45
  6. Indonesia has the world’s second-highest tuberculosis (TB) burden, with 969,000 annual TB infections. In 2017, Indonesia faced significant challenges in TB care, with 18% of cases missed, 29% of diagnosed case...

    Authors: Sarah Saragih, Firdaus Hafidz, Aditia Nugroho, Laurel Hatt, Meghan O’Connell, Agnes Caroline, Cheryl Cashin, Syed Imran, Yuli Farianti, Ackhmad Afflazier, Tiara Pakasi and Nurul Badriyah
    Citation: Health Economics Review 2024 14:44
  7. Rare diseases pose immense challenges for healthcare systems due to their low prevalence, associated disabilities, and attendant treatment costs. Advancements in gene therapy, such as treatments for Spinal Mus...

    Authors: Qin Xiang Ng, Clarence Ong, Kai En Chan, Timothy Sheng Khai Ong, Isabelle Jia Xuan Lim, Ansel Shao Pin Tang, Hwei Wuen Chan and Gerald Choon Huat Koh
    Citation: Health Economics Review 2024 14:42
  8. The sustenance of any household is tied to the well-being of the mother's health before, during, and after pregnancy. Maternal health care has continued a downward slope, increasing maternal mortality in rural...

    Authors: Mobolaji Victoria Adejoorin, Kabir Kayode Salman, Kemisola Omorinre Adenegan, Ogheneruemu Obi-Egbedi, Magbagbeola David Dairo and Abiodun Olusola Omotayo
    Citation: Health Economics Review 2024 14:40
  9. Although countries worldwide have launched a series of pro-competition reforms, the literature on the impacts of hospital competition has produced a complex and contradictory picture. This study examined wheth...

    Authors: Zixuan Peng, Audrey Laporte, Xiaolin Wei, Xinping Sha and Peter C. Coyte
    Citation: Health Economics Review 2024 14:39
  10. Relapsed or refractory classic Hodgkin lymphoma (RRcHL) associates with poor prognosis and heavy disease burden to patients. This study evaluated the cost-effectiveness of brentuximab vedotin (BV) in compariso...

    Authors: Shitong Xie, Yanan Sheng, Ling-Hsiang Chuang and Jing Wu
    Citation: Health Economics Review 2024 14:38
  11. Recently, the endovascular treatment (EVT) of acute ischemic stroke has made significant progress in many aspects. Intravenous thrombolysis (IVT) is usually recommended before endovascular treatment in clinica...

    Authors: Lu Han, Kuixu Lan, Dejian Kou, Zehua Meng, Jin Feng, Elizabeth Maitland, Stephen Nicholas and Jian Wang
    Citation: Health Economics Review 2024 14:37
  12. Earlier studies have estimated the impact of increased body mass index (BMI) on healthcare costs. Various methods have been used to avoid potential biases and inconsistencies. Each of these methods measure dif...

    Authors: Christina Hansen Edwards, Johan Håkon Bjørngaard, Jonas Minet Kinge, Gunnhild Åberge Vie, Vidar Halsteinli, Rønnaug Ødegård, Bård Kulseng and Gudrun Waaler Bjørnelv
    Citation: Health Economics Review 2024 14:36
  13. Estimating program costs when planning community-based mental health programs can be burdensome. Our aim was to retrospectively document the cost for the first year of planning and implementing Healthy Minds H...

    Authors: Sharmily Roy, Henry Shelton Brown III, Lisa Sanger Blinn, Sarah Carter Narendorf and Jane E. Hamilton
    Citation: Health Economics Review 2024 14:35

    The Correction to this article has been published in Health Economics Review 2024 14:49

  14. Due to population aging, healthcare expenditure is projected to increase substantially in developed countries like Spain. However, prior research indicates that health status, not merely age, is a key driver o...

    Authors: Jorge-Eduardo Martínez-Pérez, Juan-Antonio Quesada-Torres and Eduardo Martínez-Gabaldón
    Citation: Health Economics Review 2024 14:33
  15. In 2022, updated guidance from NICE expanded the options for self-monitoring of blood glucose for patients with type 2 diabetes (T2DM), to include continuous glucose monitoring (CGM). In this budget impact ana...

    Authors: Murtada Alsaif, Ali Farhat, Zoe Blumer and Leela Barham
    Citation: Health Economics Review 2024 14:32
  16. Biosimilars are biologic drugs that have the potential to increase the efficiency of healthcare spending and curb drug-related cost increases. However, their introduction into hospital formularies through init...

    Authors: Marko Krstic, Jean-Christophe Devaud, Farshid Sadeghipour and Joachim Marti
    Citation: Health Economics Review 2024 14:31
  17. There are no standards in diagnostic and therapeutic approaches to eye care in incomplete eyelid closure due to unresolved facial palsy (FP). Loading of the upper eyelid (UELL) with gold weights (GWs) or plati...

    Authors: Izabela Nowak-Gospodarowicz, Marcin Gospodarowicz and Marek Rękas
    Citation: Health Economics Review 2024 14:30
  18. Sample surveys are extensively used to provide reliable direct estimates for large areas or domains with enough sample sizes at national and regional levels. However, zones are unplanned domains by the Demogra...

    Authors: Yegnanew A. Shiferaw, Seyifemickael Amare Yilema and Yikeber Abebaw Moyehodie
    Citation: Health Economics Review 2024 14:29
  19. Many countries has introduced pro-competition policies in the delivery of healthcare to improve medical quality, including China. With the increasing intensity of competition in China's healthcare market, ther...

    Authors: Yinghui Lu, Qingling Jiang, Xueli Zhang, Xiaojun Lin and Jay Pan
    Citation: Health Economics Review 2024 14:28
  20. Based on the legal framework laid down in section 130b (9) of Book V of the German Social Code, various criteria are relevant for the negotiated price for new patented drugs in Germany. European reference pric...

    Authors: Iris an der Heiden, Guido Schiffhorst, Laura Müller, Martin Albrecht, Arne Bartol and Stefanie Wiberny
    Citation: Health Economics Review 2024 14:27
  21. To estimate the long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin as an add-on therapy for type 2 diabetes patients inadequately controlled on metformin in China, to better inform heal...

    Authors: Shuyan Gu, Jinghong Gu, Xiaoyong Wang, Xiaoling Wang, Lu Li, Hai Gu and Biao Xu
    Citation: Health Economics Review 2024 14:26
  22. Morocco is engaged in a health system reform aimed at generalizing health insurance across the whole population by 2025. This study aims to build a national database of costs at all levels of public hospitals ...

    Authors: El Houcine Akhnif, Abdelouahab Belmadani, Awad Mataria and Maryam Bigdeli
    Citation: Health Economics Review 2024 14:25
  23. Barriers to utilization of sexual and reproductive health (SRH) services by adolescents and young people (AYP) have persisted despite evidence that youth-friendly services have a positive effect on contracepti...

    Authors: Olujide Arije, Jason Madan and Tintswalo Hlungwani
    Citation: Health Economics Review 2024 14:24
  24. Authors: Shohei Okamoto, Mizuki Sata, Megumi Rosenberg, Natsuko Nakagoshi, Kazuki Kamimura, Kohei Komamura, Erika Kobayashi, Junko Sano, Yuzuki Hirazawa, Tomonori Okamura and Hiroyasu Iso
    Citation: Health Economics Review 2024 14:20

    The original article was published in Health Economics Review 2024 14:8

  25. In response to the imperatives of universal health coverage, structural factors that may hinder the effectiveness of increased spending in sub-Saharan Africa (SSA) need attention. This study assessed the media...

    Authors: Wa Ntita Serge Kabongo and Josue Mbonigaba
    Citation: Health Economics Review 2024 14:14
  26. Traumatic injuries are rising globally, disproportionately affecting low- and middle-income countries, constituting 88% of the burden of surgically treatable conditions. While contributing to the highest burde...

    Authors: Pakwanja Twea, David Watkins, Ole Frithjof Norheim, Boston Munthali, Sven Young, Levison Chiwaula, Gerald Manthalu, Dominic Nkhoma and Peter Hangoma
    Citation: Health Economics Review 2024 14:13

    The Correction to this article has been published in Health Economics Review 2024 14:41

  27. Multiple sclerosis (MS) is a chronic, autoimmune, and inflammatory disease. The economic burden of MS is substantial, and the high cost of Disease-modifying drugs (DMDs) prices are the main drivers of healthca...

    Authors: Nasrin Abulhasanbeigi Gallehzan, Majid Khosravi, Khosro Jamebozorgi, Nazanin Mir, Habib Jalilian, Samira Soleimanpour, Saeed Hoseini, Aziz Rezapour and Abbas Eshraghi
    Citation: Health Economics Review 2024 14:12
  28. Adverse drug events (ADEs) are not only a safety and quality of care issue for patients, but also an economic issue with significant costs. Because they often occur during hospital stays, it is necessary to ac...

    Authors: Maxime Durand, Christel Castelli, Clarisse Roux-Marson, Jean-Marie Kinowski and Géraldine Leguelinel-Blache
    Citation: Health Economics Review 2024 14:11
  29. Studies that examine the broad allocation of resources, regardless of who bears the costs, should ideally estimate costs from a societal perspective. We have successfully integrated survival rates, employment ...

    Authors: Fuhmei Wang, Jing-Shiang Hwang, Wen-Yen Huang, Yu-Tzu Chang and Jung-Der Wang
    Citation: Health Economics Review 2024 14:10
  30. Federally qualified health centers (FQHCs) are integral to the U.S. healthcare safety net and uniquely situated in disadvantaged neighborhoods. The 2009 American Recovery and Reinvestment Act (ARRA) invested $...

    Authors: Elizabeth L. Tung, Nour Asfour, Joshua D. Bolton, Elbert S. Huang, Calvin Zhang and Luc Anselin
    Citation: Health Economics Review 2024 14:9
  31. Universal health coverage means that all people can access essential health services without incurring financial hardship. Even in countries with good service coverage and financial protection, the progress to...

    Authors: Shohei Okamoto, Mizuki Sata, Megumi Rosenberg, Natsuko Nakagoshi, Kazuki Kamimura, Kohei Komamura, Erika Kobayashi, Junko Sano, Yuzuki Hirazawa, Tomonori Okamura and Hiroyasu Iso
    Citation: Health Economics Review 2024 14:8

    The Correction to this article has been published in Health Economics Review 2024 14:20

  32. Clinical trials have demonstrated the efficacy of edaravone dexborneol in the treatment of acute ischemic stroke. This study aims to determine the cost-effectiveness of edaravone dexborneol compared with human...

    Authors: Pingyu Chen, Mengjie Luo, Yanqiu Chen, Yanlei Zhang, Chao Wang and Hongchao Li
    Citation: Health Economics Review 2024 14:7
  33. Health economics is a thriving sub-discipline of economics. Applied health economics research is considered essential in the health care sector and is used extensively by public policy makers. For scholars, it...

    Authors: Clara C. Zwack, Milad Haghani and Esther W. de Bekker-Grob
    Citation: Health Economics Review 2024 14:6
  34. While COVID-19 hospitalization costs are essential for policymakers to make informed health care resource decisions, little is known about these costs in western Europe. The aim of the current study is to anal...

    Authors: Leslie R. Zwerwer, Jan Kloka, Simon van der Pol, Maarten J. Postma, Kai Zacharowski, Antoinette D. I. van Asselt and Benjamin Friedrichson
    Citation: Health Economics Review 2024 14:4
  35. This study compared the clinical efficacy and cost-effectiveness of parenteral iron, using intravenous iron sucrose (IVIS) therapy against the standard regimen of oral iron (OI) therapy for managing iron-defic...

    Authors: Somen Saha, Devang Raval, Komal Shah and Deepak Saxena
    Citation: Health Economics Review 2024 14:3
  36. Upcoding in Medicare has been a topic of interest to economists and policy makers for nearly 40 years. While upcoding is generally understood as “billing for services at higher level of complexity than the ser...

    Authors: Keith A. Joiner, Jianjing Lin and Juan Pantano
    Citation: Health Economics Review 2024 14:1

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 2.7
    5-year Journal Impact Factor: 2.8
    Source Normalized Impact per Paper (SNIP): 1.218
    SCImago Journal Rank (SJR): 0.800

    Speed 2023
    Submission to first editorial decision (median days): 7
    Submission to acceptance (median days): 220

    Usage 2023
    Downloads: 566,888
    Altmetric mentions: 483